Clinical trials: Axillary Hyperhidrosis
Axillary Hyperhidrosis
Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-302)
Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of…
- Trial name
- CARDIGANII (NCT03948646)
- Testing
- Sofpironium Bromide, 15%, Vehicle
- Where
- 42 sites in United States
- Volunteers
- 351 people
- Sponsor
- Botanix Pharmaceuticals
Hyperhidrosis
Characterization of Exposure From Topical Administration of [14C] Umeclidinium to Axilla or Palm of Healthy Male Subjects
The purpose of this study is to characterize the pharmacokinetics (PK), safety and tolerability of topically applied umeclidinium following single dose topical administration.
- Trial name
- NCT01934153
- Testing
- [14C]Umeclidinium 18.5 mg
- Where
- Netherlands
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Primary Axillary Hyperhidrosis
Assessment of Safety, Tolerability and Efficacy of 1% GPB Cream Versus Qbrexza® (Glycopyrronium) Cloth 2.4% Under Maximum-Use Conditions in Subjects with Primary Axillary Hyperhidrosis
The aim of this study is to investigate the safety, tolerability and efficacy of 1% GPB Cream compared to Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use under maximum use conditions.
- Trial name
- NCT04159610
- Testing
- WO3970, Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use
- Sponsor
- Dr. August Wolff GmbH & Co. KG Arzneimittel
Primary Axillary Hyperhidrosis
Ulthera® System for Treating Axillary Hyperhidrosis
Up to 20 enrolled subjects will be treated. Subjects will receive two Ulthera® treatments on the axillas provided 30 days apart. Follow-up visits will occur at 7, 30, 90 and 180 days following the last treatment.
- Trial name
- NCT02286765
- Testing
- Ulthera System treatment
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Ulthera, Inc
Primary Axillary Hyperhidrosis
Fractional Micro-Needle Radiofrequency and I Botulinum Toxin A for Primary Axillary Hyperhidrosis
Because of the limiting data about an efficacy and safety of fractional radiofrequency for the treatment of hyperhidrosis, this study aim to compare clinical efficacy by Hyperhidrosis Disease Severity Score (HDSS) between…
- Trial name
- NCT03054480
- Testing
- Fractional Micro-Needle Radiofrequency, Botulinum toxin type A
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Mae Fah Luang University Hospital
Hyperhidrosis
Pharmacokinetic, Safety, Tolerability, and Clinical Effect of Topical Umeclidinium in Primary Axillary Hyperhidrosis
This is a double blind (sponsor unblind), repeat dose, randomized, parallel group, placebo controlled study to assess the pharmacokinetic parameters, safety, tolerability, and clinical effect of topically applied umeclidinium…
- Trial name
- NCT02563899
- Testing
- Umeclidinium, Vehicle
- Where
- 3 sites in United States, Canada
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
Primary Axillary Hyperhidrosis
Clinical Trial to Evaluate ANT-1403 in the Treatment of Primary Axillary Hyperhidrosis
The purpose of this study is to confirm the effect of ANT-1403 in the treatment of primary axillary hyperhidrosis.
- Trial name
- NCT01799824
- Testing
- ANT-1403
- Where
- 9 sites in United States
- Volunteers
- 52 people
- Sponsor
- Anterios Inc.
Primary Axillary Hyperhidrosis
A Safety Study of BBI-4000 Gel in Patients With Axillary Hyperhidrosis
Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of…
- Trial name
- NCT03627468
- Testing
- Sofpironium Bromide Gel, 5%, Sofpironium Bromide Gel, 15%
- Where
- 12 sites in United States
- Volunteers
- 300 people
- Sponsor
- Botanix Pharmaceuticals
Hyperhidrosis, Axillary Hyperhidrosis
miraDry Post Market Tumescent Anesthesia Study
This clinical trial will collect data on the safety and efficacy of the miraDry treatment when High Volume Anesthesia (Tumescent Anesthesia) is used as an alternate method of anesthetizing the axilla prior to the miraDry System…
- Trial name
- NCT05546710
- Testing
- miraDry treatment
- Volunteers
- healthy volunteers welcome
- Sponsor
- miraDry, Inc.
Hyperhidrosis
Study of Glycopyrronium in Axillary Hyperhydrosis
The study is a randomized, double-blind, vehicle controlled, parallel group study, designed to assess the efficacy and safety of glycopyrronium topical wipes, once daily, compared to vehicle in subjects with axillary…
- Trial name
- NCT02530281
- Testing
- glycopyrronium Topical Wipes, Vehicle
- Where
- 31 sites in United States, Germany
- Volunteers
- 344 people
- Sponsor
- Journey Medical Corporation
Hyperhidrosis Primary Focal Axilla
Longevity of Microwave Thermolysis and Botulinum Toxin A for Treatment of Axillary Hyperhidrosis
This trial aims is to assess and compare treatment effect of microwave thermolysis and botulinum toxin A for axillary hyperhidrosis with focus on longevity.
- Trial name
- NCT05057117
- Testing
- Microwave thermolysis, Botulinum toxin A
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- Merete Haedersdal
Axillary Hyperhidrosis
Botox and Suction-Curettage for Treatment of Excessive Underarm Sweating (Axillary Hyperhidrosis)
The purpose of this study is to compare the effectiveness of two methods in the treatment of excessive underarm sweating (axillary hyperhidrosis): suction-curettage and Botox injections.
- Trial name
- NCT01274611
- Testing
- Botulinum Toxin Type A, Suction-Curettage
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Hyperhidrosis
Safety and Efficacy of an Anticholinergic Agent for Treatment of Primary Axillary Hyperhidrosis
This Phase 2 study is designed to evaluate multiple doses of an anticholinergic-containing medication and identify the dose or doses that may effectively reduce axillary sweating in hyperhidrotic subjects.
- Trial name
- NCT02193139
- Testing
- WL8713, 6 mg, WL8713, 12 mg, WL8713, 18 mg
- Where
- United States
- Volunteers
- 195 people
- Sponsor
- Watson Pharmaceuticals
Essential Axillary Hyperhidrosis
Unicentric Comparing Study of Suction Curettage With Standard BOTOX Injection in the Treatment of Patients With Essential Axillar Hyperhidrosis: Comparing of Efficacy, Duration of Effectiveness, and Adverse Events.
Part 1: patients with essential hyperhidrosis are treated one time with suction curettage in both axillae. Part 2: patients with axillary hyperhidrosis receive one treatment with suction curettage in one axilla, and at the same…
- Trial name
- NCT00669474
- Testing
- Suction curettage, Treatment with Botox
- Where
- Belgium
- Volunteers
- 25 people
- Sponsor
- University Hospital, Ghent
Hyperhidrosis
Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis
The purpose of the study is to assess the safety of 2 doses of glycopyrrolate compared to 2 doses of glycopyrronium and vehicle (5 treatment arms) for the treatment of axillary hyperhidrosis when applied once daily for 4 weeks…
- Trial name
- NCT02129660
- Testing
- Dose 1 of glycopyrrolate, 2.0% QD, Dose 2 of glycopyrrolate, 3.0% QD, Dose 1 of glycopyrronium, 2.5% QD
- Where
- 15 sites in United States, Canada
- Volunteers
- 105 people
- Sponsor
- Journey Medical Corporation
Axillary Hyperhidrosis
Tx Axillary Hyperhidrosis 1210nm Diode Laser
Primary axillary hyperhidrosis is a common idiopathic disorder of the eccrine sweat glands that interferes with daily activities and causes significant social distress.
- Trial name
- NCT02105753
- Testing
- 1210nm Diode Laser treatments
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- United States Naval Medical Center, San Diego
Axillary Hyperhidrosis
Evaluation of the Ulthera System for Treating Axillary Hyperhidrosis
To evaluate the Ulthera System and the 7-3.0mm transducer for treating axillary hyperhidrosis.
- Trial name
- ULT-218 (NCT03320096)
- Testing
- Microfocused ultrasound with visualization
- Where
- 2 sites in Germany
- Volunteers
- 20 people
- Sponsor
- Ulthera, Inc
Primary Axillary Hyperhidrosis
A Safety Study of BBI-4000 Gel in Pediatric Patients With Axillary Hyperhidrosis
Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of…
- Trial name
- NCT03785587
- Testing
- Sofpironium Bromide Gel, 15%
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Botanix Pharmaceuticals
Hyperhidrosis Primary Focal Axilla
Evaluation of Safety and Efficacy of Morpheus8 Applicator for the Treatment of Focal Hyperhidrosis of the Axillae Using Radio Frequency
The InMode radio frequency Pro System with the Morpheus8 Applicator is a computerized system generating radio frequency energy, based on the underlying technology of Fractional RF.
- Trial name
- NCT05860972
- Testing
- Morpheus8 Applicator (with the 24 pin tip) in the treatment of primary axillary hyperhidrosis.
- Where
- 4 sites in United States, Israel
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- InMode MD Ltd.
Axillary Hyperhidrosis
Comparison of the Clinical Efficacy and Adverse Reactions of Different Needling Patterns of High-frequency Microneedles in the Treatment of Axillary Odor
Background: Axillary osmidrosis is a common skin disease characterized by an unpleasant odor produced when secretions from apocrine sweat glands in the armpits are decomposed by bacteria on the skin.
- Trial name
- NCT07094009
- Testing
- received transverse needling, received vertical needling, received mixed needling
- Where
- China
- Volunteers
- 90 people
- Sponsor
- First Affiliated Hospital of Chongqing Medical University